[1]王涛.匹维溴铵联合益气和胃胶囊治疗腹泻型肠易激综合征与功能性消化不良重叠患者的疗效及其对血清炎症因子水平的影响[J].新乡医学院学报,2023,40(4):361-365.[doi:10.7683/xxyxyxb.2023.04.012]
　WANG Tao.Effect of pinaverium bromide combined with Yiqi Hewei capsule in the treatment of diarrhea-type irritable bowel syndrome overlapsing with functional dyspepsia patients and its influence on serum inflammatory factors[J].Journal of Xinxiang Medical University,2023,40(4):361-365.[doi:10.7683/xxyxyxb.2023.04.012]
点击复制

匹维溴铵联合益气和胃胶囊治疗腹泻型肠易激综合征与功能性消化不良重叠患者的疗效及其对血清炎症因子水平的影响
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
40卷
期数:
2023年4
页码:
361-365
栏目:
临床研究
出版日期:
2023-04-05

文章信息/Info

Title:
Effect of pinaverium bromide combined with Yiqi Hewei capsule in the treatment of diarrhea-type irritable bowel syndrome overlapsing with functional dyspepsia patients and its influence on serum inflammatory factors
作者:
王涛
（许昌市中心医院消化科，河南　许昌　461001）
Author(s):
WANG Tao
（Department of Gastroenterology,Xuchang Central Hospital,Xuchang 461001,Henan Province,China）
关键词:
益气和胃胶囊; 匹维溴铵; 功能性消化不良; 腹泻型肠易激综合征
Keywords:
Yiqi Hewei capsule; pinaverium bromide; functional dyspepsia; diarrhea-type irritable bowel syndrome
分类号:
R574
DOI:
10.7683/xxyxyxb.2023.04.012
文献标志码:
A
摘要:
目的探讨匹维溴铵联合益气和胃胶囊治疗腹泻型肠易激综合征（IBS-D）与功能性消化不良（FD）重叠患者的临床效果及其对患者血清炎症因子水平的影响。方法选择2019年1月至2021年1月许昌市中心医院消化科收治的120例IBS-D与FD症状重叠患者为研究对象，按简单随机数字表法将患者分为对照组和观察组，每组60例。对照组患者给予匹维溴铵片，每次50 mg口服，每日3 次，连续治疗4周；观察组在对照组治疗基础上给予益气和胃胶囊，每次 2 g口服，每日3 次，连续治疗4周。于治疗前后，采用症状评分量表评估2组患者的临床症状，SF-36生活质量评分表评估2组患者的生活质量；应用酶联免疫吸附试验法检测患者血清中肿瘤坏死因子-α（TNF-α）、白细胞介素（IL）-6以及IL-8水平。比较2组患者的临床疗效和不良反应。结果治疗前，2组患者的腹胀评分、腹痛评分、腹泻评分、临床症状总分及生活质量评分比较差异无统计学意义（P>0.05）；2组患者治疗后的腹胀评分、腹痛评分、腹泻评分及临床症状总分显著低于治疗前，生活质量评分显著高于治疗前（P<0.05）。治疗后，观察组患者的腹胀评分、腹痛评分、腹泻评分及临床症状总分显著低于对照组，生活质量评分显著高于对照组（P<0.05）。对照组和观察组患者的临床总有效率分别为76.67%（46/60）、93.33（56/60），观察组患者的临床总有效率显著高于对照组（χ2=10.382，P<0.05）。治疗前，对照组与观察组患者血清TNF-α、IL-6和IL-8水平比较差异无统计学意义（P>0.05）。2组患者治疗后血清TNF-α、IL-6和IL-8水平显著低于治疗前，观察组患者治疗后血清TNF-α、IL-6和IL-8水平显著低于对照组（P<0.05）。治疗后2组患者肝肾功能均无异常，无皮疹、乏力、呕吐、腹泻加重等不良反应；2组患者的不良反应发生率比较差异无统计学意义（χ2=3.382，P>0.05）。结论匹维溴铵联合益气和胃胶囊可显著缓解IBS-D与FD重叠患者的临床症状，提高生活质量，其作用机制可能是通过有效降低血清炎症因子TNF-α、IL-6和IL-8水平，减轻胃肠道炎症反应，从而协调胃肠道正常运动。
Abstract:
ObjectiveTo investigate the effect of pinaverium bromide combined with Yiqi Hewei capsule in the treatment of patients with diarrhea predominant irritable bowel syndrome(IBS-D) overlaping with functional dyspepsia(FD) and its influence on the level of serum inflammatory factors.MethodsA total of 120 patients with IBS-D overlapsing with FD admitted to the Department of Gastroenterology,Xuchang Central Hospital from January 2019 to January 2021 were selected as the study subjects,and the patients were randomly divided into the control group and observation group,with 60 cases in each group.The patients in the control group were treated with pinaverium bromide tablets,50 mg each time,orally,3 times a day,for 4 consecutive weeks;on the basis of the treatment in the control group,the patients in the observation group were treated with Yiqi Hewei capsule,2 g each time,orally,3 times a day,for 4 consecutive weeks.Before and after treatment,the clinical symptoms of the patients in the both groups were evaluated with the symptom scoring scale,and the quality of life of the patients in the two groups was evaluated with the SF-36 quality of life scoring scale;the levels of tumor necrosis factor-α(TNF-α),interleukin (IL)-6 and IL-8 in serum of patients were detected by enzyme-linked immunosorbent assay in the two groups.The clinical efficacy and adverse reactions of patients between the two groups were compared.ResultsBefore treatment,there was no significant difference in abdominal distension score,abdominal pain score,diarrhea score,total clinical symptom score and quality of life score of patients between the two groups (P>0.05).After treatment,the abdominal distension score,abdominal pain score,diarrhea score and total clinical symptom score of patients in the both groups were significantly lower than those before treatment,the quality of life score was significantly higher than that before treatment (P<0.05).After treatment,the abdominal distension score,abdominal pain score,diarrhea score and the total score of clinical symptoms of patients in the observation group were significantly lower than those in the control group,the quality of life score was significantly higher than that in the control group (P<0.05).The total clinical effective rates of patients in the two groups were 76.67% (46/60) and 93.33 (56/60),respectively;the total clinical effective rate of patients in the observation group was significantly higher than that in the control group（χ2=10.382,P<0.05）.Before treatment,there was no significant difference in the levels of TNF-α,IL-6 and IL-8 in serum of patients between the control group and observation group(P>0.05).After treatment,the levels of serum IL-6,IL-8 and TNF-α of patients in the both groups were significantly lower than those before treatment (P<0.05);the levels of TNF-α,IL-6 and IL-8 in serum of patients in the observation group were significantly lower than those in the control group (P<0.05).After treatment,the liver and kidney functions of the patients in both groups were normal,and there were no adverse reactions such as rash,fatigue,vomiting,diarrhea aggravation,etc;there was no significant difference in the incidence of adverse reactions between the two groups(χ2=3.382，P>0.05）.ConclusionPinaverium bromide combined with Yiqi Hewei capsule can significantly relieve the clinical symptoms of patients with IBS-D overlapsing with FD,and improve the quality of life of patients.Its mechanism may be to effectively reduce the levels of inflammatory factors IL-6,IL-8 and TNF-α,reduce the inflammatory reaction of gastrointestinal tract,so as to coordinate the normal movement of gastrointestinal tract.

参考文献/References:

［1］　陈磊,陈莉丽,全俊,等.肠易激综合征与功能性消化不良重叠的治疗进展［J］.胃肠病学和肝病学杂志,2014,23(3):350-352.
CHEN L,CHEN L L,QUAN J,et al.Treatment progress of overlap between irritable bowel syndrome and functional dyspepsia［J］.Chin J Gastroenterol Hepatol,2014,23(3):350-352.
［2］　汪晓茹,汪红兵,娄颜,等.210 例功能性消化不良重叠腹泻型肠易激综合征的证候规律［J］.中国中西医结合消化杂志,2017,25(6):449-452.
WANG X R,WANG H B,LOU Y,et al.Syndrome rule of 210 cases of functional dyspepsia overlap diarrhea predominant of irritable bowel syndrome［J］.Chin J Integr Tradit Western Med Digest,2017,25(6):449-452.
［3］　杨倩.辛开苦降法治疗功能性消化不良重叠腹泻型肠易激综合征的临床疗效观察［D］.南京:南京中医药大学,2022.
YANG Q.Clinical effect of XinKaiKuJiang method in treating functional dyspipsia overlapping diarrhea irritable bowel［D］.Nanjing:Nanjing University of Chinese Medicine,2022.
［4］　赵斌,郭联斌,段武琼.肠易激综合征血清炎症因子表达与肠道菌群变化的关系［J］.现代消化及介入诊疗,2019,24(9):1046-1049.
ZHAO B,GUO L B,DUAN W Q.Relationship between the expression of serum inflammatory factors and the changes of intestinal flora in irritable bowel syndrome［J］.Mod Digest Interv,2019,24(9):1046-1049.
［5］　孙晓红.功能性消化不良的罗马Ⅳ标准解读［J］.中华全科医师杂志,2017,16(9):661-663.
SUN X H.Interpretation of Rome IV criteria for functional dyspepsia［J］.Chin J Gen Practit,2017,16(9):661-663.
［6］　BAI T,XIA J,JIANG Y D,et al.Comparison of the Rome IV and Rome III criteria for IBS diagnosis:a cross-sectional survey［J］.J Gastroenterol Hepatol,2017(5)：1018-1025.
［7］　岑永豪.双歧杆菌四联活菌联合谷维素治疗肠易激综合征的临床观察［J］.实用药物与临床,2013,16(1):22-24.
CHEN Y H.Clinical observation of tetralogy of viable bifidobacterium combined with oryzanol treatment for irritable bowel syndrome［J］.Pract Pharm Clin Remed,2013,16(1):22-24.
［8］　项忆瑾,林江.消化不良症状量表和生活质量量表评价功能性消化不良的研究进展［J］.胃肠病学,2015,20(3):180-183.
XIANG Y J,LIN J.Advances in study on evaluation of functional dyspepsia by dyspepsia symptom scale and quality of life questionnaire［J］.Chin J Gastroenterol,2015,20(3):180-183.
［9］　汪正芳,张声生.调肝理脾法治疗腹泻型肠易激综合征症状疗效观察［J］.世界中医药,2015,10(5):699-702.
WANG Z F,ZHANG S S.Clinical observation on treatment of irritable bowel syndrome with diarrhea (IBS-D) by regulating liver and spleen［J］.World Chin Med,2015,10(5):699-702.
［10］　李鲁,王红妹,沈毅.SF-36健康调查量表中文版的研制及其性能测试［J］.中华预防医学杂志,2002,36(2):109-113．
LI L,WANG H M,SHEN Y.Development and psychometric tests of a Chinese version of the SF-36 Health Survey Scales［J］.Chin J Prevent Med,2002,36(2):109-113．
［11］　朱创键.双歧三联活菌胶囊联合参苓白术散对腹泻型IBS患者血浆SS和NPY水平影响及疗效观察［J］.中国微生态学杂志,2015,27(5):552-554,557.
ZHU C J.Influence and efficacy of Bifid Triple Viable Capsules combined with Shenling Baizhu Powder on plasma somatostatin and neuropeptide Y levels of patients with diarrhea & irritable bowel syndrom［J］.Chin J Microecol,2015,27(5):552-554,557.
［12］　苏亚兵,王宁,屈增强.功能性消化不良中西医研究进展［J］.临床医学研究与实践,2017,2(21):197-198.
SU Y B,WANG N,QU Z Q.Research progress of functional dyspepsia in Chinese and western medicine［J］.Clin Res Pract,2017,2(21):197-198.
［13］　吴柏瑶,张法灿,梁列新.功能性消化不良的流行病学［J］.胃肠病学和肝病学杂志,2013,22(1):85-90.
WU B Y,ZHANG F C,LIANG L X.Epidemiology of functional dyspepsia［J］.Chin J Gastroenterol Hepatol,2013,22(1):85-90.
［14］　张杰,李红,王进海,等.肠道微生态对腹泻型肠易激综合征的影响及其作用机制探讨［J］.世界临床药物,2019,40(5):340-346.
ZHANG J,LI H,WANG J H,et al.The effect and mechanism of intestinal microbiota in the pathogenesis of diarrhea type irritable bowel syndrome［J］.World Clin Drugs,2019,40(5):340-346.
［15］　张宇迪,刘纯伦.功能性消化不良与脑-肠轴［J］.胃肠病学和肝病学杂志,2019,28(8):939-941,946.
ZHANG Y D,LIU C L.Functional dyspepsia and the brain-gut axis［J］.Chin J Gastroenterol Hepatol,2019,28(8):939- 941,946.
［16］　李海龙,任维,李彦敏,等.肠易激综合征相关致病因素及发病机制研究进展［J］.医学与哲学(B),2017,38(2):73-76.
LI H L,REN W,LI Y M,et al.The advances on the pathogenic factor and pathogenesis of irritable bowel syndrome［J］.Med Philos(B),2017,38(2):73-76.
［17］　李爱茹.中药对IBS-D大鼠胃肠动力及内脏感觉调节机制的研究［D］.天津:天津医科大学,2008.
LI A R.Study on the regulation mechanism of traditional Chinese medicine on gastrointestinal motility and visceral sensation in IBS-D rats［D］.Tianjin:Tianjin Medical University,2008.
［18］　牛冰玉.IBS-D患者中医证型与血清炎症因子及肠黏膜TLR4/NF-κB的关系［D］.北京：北京中医药大学,2021.
NIU B Y.Relationship of TCM syndrome types and serum inflammatory factors and TLR4/NF- κ B in intestinal mucosal of IBS-D patients［D］.Beijing:Beijing University of Chinese Medicine,2021.
［19］　张竹,李文兵,徐梦军.匹维溴铵治疗肠易激综合征的疗效分析与评价［J］.临床合理用药杂志,2011,4(30):43-45.
ZHANG Z,LI W B,XU M J.Therapeutic effects of pinaverium bromide on irritable bowel syndrome［J］.Chin J Clin Rat Drug Use,2011,4(30):43-45.
［20］　赵良存,智万发.益气和胃胶囊的制备及临床应用［J］.中国社区医师(医学专业),2010,12 (14):29.
ZHAO L C,ZHI W F.Preparation and clinical application of Yiqi Hewei capsule［J］.Chin Comm Doctors,2010,12(14):29.

更新日期/Last Update: 2023-04-05